Dupixent (dupilumab) has been a genuine breakthrough for many families. For children with moderate-to-severe eczema, asthma, and other inflammatory conditions, it has offered meaningful relief when ...

If you or someone you love uses Dupixent, you may have recently seen television ads or online headlines linking the medication to rare forms of cancer. For many patients, this has caused confusion, ...

Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD) last fall. Most COPD treatments ...

The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary disease ...

The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for treating adults with bullous pemphigoid (BP), a chronic and debilitating skin disease primarily affecting the elderly ...

PARIS (Reuters) - Drugmakers Sanofi and Regeneron said on Saturday results from a one-year test of their Dupixent product aimed at adults with eczema or moderate-to-severe atopic dermatitis (AD) had ...

Allergic fungal rhinosinusitis (AFRS) is a long-term inflammatory sinus condition. It happens when fungus, such as mold, grows in your nasal passages and your immune system has a strong allergic ...

A Nektar Therapeutics drug has met the skin clearance goals of a closely watched mid-stage clinical trial in atopic dermatitis. While these preliminary results bring validation to the therapy’s novel ...

SNY's Dupixent is expanding into new diseases and geographies, strengthening its position as a key driver of long-term revenue growth.